115 related articles for article (PubMed ID: 29858236)
1. Effectiveness, Complications, and Costs of Rheumatoid Arthritis Treatment with Biologics in Alberta: Experience of Indigenous and Non-indigenous Patients.
Barnabe C; Zheng Y; Ohinmaa A; Crane L; White T; Hemmelgarn B; Kaplan GG; Martin L; Maksymowych WP
J Rheumatol; 2018 Oct; 45(10):1344-1352. PubMed ID: 29858236
[TBL] [Abstract][Full Text] [Related]
2. Effect of remission definition on healthcare cost savings estimates for patients with rheumatoid arthritis treated with biologic therapies.
Barnabe C; Thanh NX; Ohinmaa A; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1600-6. PubMed ID: 25028381
[TBL] [Abstract][Full Text] [Related]
3. Healthcare service utilisation costs are reduced when rheumatoid arthritis patients achieve sustained remission.
Barnabe C; Thanh NX; Ohinmaa A; Homik J; Barr SG; Martin L; Maksymowych WP
Ann Rheum Dis; 2013 Oct; 72(10):1664-8. PubMed ID: 23117244
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported Outcomes, Resource Use, and Social Participation of Patients with Rheumatoid Arthritis Treated with Biologics in Alberta: Experience of Indigenous and Non-indigenous Patients.
Barnabe C; Crane L; White T; Hemmelgarn B; Kaplan GG; Martin L; Maksymowych WP
J Rheumatol; 2018 Jun; 45(6):760-765. PubMed ID: 29449496
[TBL] [Abstract][Full Text] [Related]
5. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
[TBL] [Abstract][Full Text] [Related]
6. Canadian estimates of health care utilization costs for rheumatoid arthritis patients with and without therapy with biologic agents.
Ohinmaa AE; Thanh NX; Barnabe C; Martin L; Russell AS; Barr SG; Maksymowych WP
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1319-27. PubMed ID: 24470178
[TBL] [Abstract][Full Text] [Related]
7. A European chart review study on early rheumatoid arthritis treatment patterns, clinical outcomes, and healthcare utilization.
Emery P; Solem C; Majer I; Cappelleri JC; Tarallo M
Rheumatol Int; 2015 Nov; 35(11):1837-49. PubMed ID: 26164150
[TBL] [Abstract][Full Text] [Related]
8. The effect of different remission definitions on identification of predictors of both point and sustained remission in rheumatoid arthritis treated with anti-TNF therapy.
Barnabe C; Homik J; Barr SG; Martin L; Maksymowych WP
J Rheumatol; 2014 Aug; 41(8):1607-13. PubMed ID: 25028371
[TBL] [Abstract][Full Text] [Related]
9. Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.
Ten Klooster PM; Oude Voshaar MAH; Fakhouri W; de la Torre I; Nicolay C; van de Laar MAFJ
Clin Rheumatol; 2019 Oct; 38(10):2727-2736. PubMed ID: 31161488
[TBL] [Abstract][Full Text] [Related]
10. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
11. Does disease activity at the start of biologic therapy influence health care costs in patients with RA?
Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Askling J; Neovius M;
Rheumatology (Oxford); 2015 Aug; 54(8):1472-7. PubMed ID: 25796560
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
Lutf A; Poil AR; Hammoudeh M
Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Costs of Not Achieving Remission in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study.
Bergman M; Zhou L; Patel P; Sawant R; Clewell J; Tundia N
Adv Ther; 2021 May; 38(5):2558-2570. PubMed ID: 33837497
[TBL] [Abstract][Full Text] [Related]
14. Risk factors, including different biologics, associated with depression and anxiety in patients with rheumatoid arthritis: a cross-sectional observational study.
Ng KJ; Huang KY; Tung CH; Hsu BB; Wu CH; Lu MC; Lai NS
Clin Rheumatol; 2020 Mar; 39(3):737-746. PubMed ID: 31823143
[TBL] [Abstract][Full Text] [Related]
15. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapy response and drug survival for females compared to males with rheumatoid arthritis: a cohort study.
Lee J; Mason R; Martin L; Barnabe C
Rheumatol Int; 2014 Oct; 34(10):1449-53. PubMed ID: 24682439
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
[TBL] [Abstract][Full Text] [Related]
18. Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis.
Kuroda T; Tanabe N; Nozawa Y; Sato H; Nakatsue T; Kobayashi D; Wada Y; Saeki T; Nakano M; Narita I
Intern Med; 2016; 55(19):2777-2783. PubMed ID: 27725536
[TBL] [Abstract][Full Text] [Related]
19. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.
Listing J; Strangfeld A; Rau R; Kekow J; Gromnica-Ihle E; Klopsch T; Demary W; Burmester GR; Zink A
Arthritis Res Ther; 2006; 8(3):R66. PubMed ID: 16600016
[TBL] [Abstract][Full Text] [Related]
20. Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up.
Cárdenas MJ; de la Fuente S; Castro-Villegas MC; Romero-Gómez M; Ruiz-Vílchez D; Calvo-Gutiérrez J; Escudero-Contreras A; Del Prado JR; Collantes-Estévez E; Font P
Rheumatol Int; 2017 Oct; 37(10):1701-1708. PubMed ID: 28597307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
